Details of the Drug
General Information of Drug (ID: DM9UF02)
| Drug Name |
Brocresine
|
||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
Brocresine; Brocresin; 555-65-7; 3-(Aminooxymethyl)-6-bromphenol; Brocresinum [INN-Latin]; Brocresina [INN-Spanish]; NSD 1055; Brocresine [USAN:INN:BAN]; UNII-11F6O06WN0; CL 54998; NSD-1055; alpha-(Aminooxy)-6-bromo-m-cresol; C7H8BrNO2; 5-((Aminooxy)methyl)-2-bromophenol; O-)4-Brom-3-hydroxybenzyl)hydroxylamin; BRN 1945736; Phenol, 5-((aminooxy)methyl)-2-bromo-; 4-Bromo-3-hydroxybenzyloxyamine; QNWOSJAGFSUDFE-UHFFFAOYSA-N; 11F6O06WN0; 5-[(Aminooxy)methyl]-2-bromophenol; m-CRESOL, alpha-(AMINOOXY)-6-BROMO-; Brocresina
|
||||||||||||||||||||||
| Indication |
|
||||||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||||||
| #Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 218.05 | |||||||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | 1.2 | ||||||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 2 | ||||||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 2 | ||||||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 3 | ||||||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Discovery agent | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||


